G. P. Talwar

G. P. Talwar   |Clyto Access

Founder and Director, National Institute of Immunlogy, India

Keynote Speaker

Expertise: Cancer immunotherapy, Vaccine, Immunocontraception

Biography: G. P. Talwar is a medical researcher working in the area of  vaccines and immunocontraception. He received BSc (Hons) and MSc (Tech) degrees from the University of Punjab, DSc from Sorbonne working at the Institute Pasteur, Paris and DSc (hc) from Bundhelkhand University .He was Alexander von Humboldt Postdoctoral Fellow at Tübingen, Stuttgart and Munchen. He joined as Associate Professor of Biochemistry in the newly created All India Institute of Medical Sciences (AIIMS), New Delhi and also worked there as Professor and Head.He was Head, ICMR-WHO Research and Training Centre in Immunology for India and South East Asia (1972–91). He was the first Director of the National Institute of Immunology (NII). He was Professor of Eminence and Senior Consultant, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi and Director Research, Talwar Research Foundation, New Delhi, India.

Presentation:

Title: Immunotherapy of Advanced stage invariably Drugs Resistant Cancers

Abstract:

Abstract:

Cancer is accounting for increasing number of deaths in all countries.If detected at an early stage, it can be surgically removed. Radiations and a fairly large number of drugs are available to take care of most cancers.However a stage arrives in many cancers that residual Drugs-resistant cancer emerges. It is metastasized,hence not removable surgically, nor controllable by radiations.At this advanced stage, many cancers start expressing ectopically the embryonic hormone hCG. Data will be presented to show that Monoclonal antibodies  against hCG can be employed to kill cancer cells, such as those of lung cancer. Some cancer cells such as those of Molt-4 lymphoblastic leukemia express hCG, but are not killed by anti-hCG antibodies alone or in presence of Complement. These cancer cells are completely eliminated by using the antibody conjugated to Curcumin, a totally safe compound.

Therapeutic antibodies are expensive for repeated intake. These require backing by a Vaccine
evoking potent anti-hCG response. We have developed a highly immunogenic recombinant Vaccine against hCG, which is amenable to industrial production for unlimited supply. Also a highly useful and already approved Vaccine by DCGI and USFDA is available. It is based on Mycobacterium indicus pranii ( MIP) , which has both preventive and therapeutic action against Myelomas and other cancers and is being used by Clinicians in India as adjunct to  other therapies for cancers. It is a potent invigoration of both humoral and cellular immune response.

Title: A Vaccine endowed with Multiple Applications and a Polyherbal formulation for Reproductive Health of Women.

Abstract:

We developed a Vaccine based on a non-pathogenic cultivable microorganism, Mycobacterium indicus pranii, which has immunotherapeutic cum immunoprophylactic properties against leprosy and tuberculosis. It is a potent invigorator of immune responses and has found use as an adjuvant in a potential Birth Control Vaccine. Given intralesionally it heals remarkably ugly ano-genital warts , and has both preventive and therapeutic action against Sp2/O Myelomas.
Also developed is a Polyherbal formulation BASANT, which has inhibitory action on N.gonorrhea, Chlamydia trachomatis, Candida tropicalis, Candida albicans and Candida glabrata, besides HIV and HPV. Given along with 3 selected Probiotics, it cures 95% of cases of recurring vaginosis. An amazing action of BASANT is to eliminate HPV16 from infected cervical cells restoring normal Pap Smear.

Related Conferences :

International Conference on Cancer Care and Cure